TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02440412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage Therapy
Description: It's a Physical Therapy manual procedure, based in Swedish technique, and applied in a standirzed way for all participants (stroke, kneading, pressure).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rest in supine
Description: It's only rest, in a clinic stretcher, with warm ambient temperature, and listening relaxing music with headphones.
Study: NCT02759978

Intervention type: OTHER
Intervention: diagnostic workup
Description: Our primary objective is to test whether the proportion of patients diagnosed correctly with the use of 18F-FDG-PET/CT, MD-CTA, and 18F-FDG-PET/MD-CTA added to the gold standard in current clinical practice, the modified Duke criteria by Li et al. 2000, is significantly higher as compared with the modified Duke criteria on itself. The gold standard is clinical judgement after clinical follow-up by a multidisciplinary team with medical specialists.

Intervention type: OTHER
Intervention: diagnostic workup
Description: Our primary objective is to test whether the proportion of patients diagnosed correctly with the use of 18F-FDG-PET/CT, MD-CTA, and 18F-FDG-PET/MD-CTA added to the gold standard in current clinical practice, the modified Duke criteria by Li et al. 2000, is significantly higher as compared with the modified Duke criteria on itself. The gold standard is clinical judgement after clinical follow-up by a multidisciplinary team with medical specialists.

Intervention type: OTHER
Intervention: diagnostic workup
Description: Our primary objective is to test whether the proportion of patients diagnosed correctly with the use of 18F-FDG-PET/CT, MD-CTA, and 18F-FDG-PET/MD-CTA added to the gold standard in current clinical practice, the modified Duke criteria by Li et al. 2000, is significantly higher as compared with the modified Duke criteria on itself. The gold standard is clinical judgement after clinical follow-up by a multidisciplinary team with medical specialists.
Study: NCT01076088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg
Description: Sitagliptin 50 mg tablet twice a day, prior to the morning and evening meal, for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg
Description: Sitagliptin 50 mg tablet twice a day, prior to the morning and evening meal, for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin 500 mg
Description: Metformin 500 mg tablet twice daily, prior to the morning and evening meal, for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg
Description: Metformin 500 mg tablet twice daily, prior to the morning and evening meal, for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Description: Sitagliptin 100 mg once daily for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets to sitagliptin or metformin for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin 850 mg
Description: Metformin 850 mg tablet twice daily, prior to the morning and evening meal, for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg
Description: Metformin 850 mg tablet twice daily, prior to the morning and evening meal, for 24 weeks.
Study: NCT01259336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole
Description: Tablet 200 mg twice daily for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treatment in cavitary pulmonary aspergillosis
Description: Anti-tussive, blood transfusion, surgical resection and bronchial artery embolisation(BAE)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treatment in cavitary pulmonary aspergillosis
Description: Anti-tussive, blood transfusion, surgical resection and bronchial artery embolisation(BAE)
Study: NCT03289195

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI Biopsy
Description: Patient will undergo percutaneous MR guided biopsy by study Breast Radiologist within 0-60 days of completing NAC.
Study: NCT02677701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin
Description: 500mg tablet over-encapsulated to match placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (for azithromycin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhaled tobramycin
Description: clinically prescribed inhaled tobramycin used by subjects participating in the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: inhaled tobramycin
Description: clinically prescribed inhaled tobramycin used by subjects participating in the study
Study: NCT02339298

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: music application
Description: music is applied during anaesthesia using headphones

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: only headphones
Description: music is not applied, only headphones are placed

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: a caudal block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: a caudal block
Study: NCT00217477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paricalcitol
Description: Given IV
Study: NCT01066416

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Sinus Surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: medical therapy
Description: Subjects will undergo surgery 6 months after randomization
Study: NCT03320629

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: apatinib S-1 radiotherapy
Description: apatinib 500mg qd po S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
Study: NCT03133468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJM347
Description: Oral administration
Study: NCT03320629

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: S-1 radiotherapy
Description: S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
Study: NCT02037919

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate Nexplanon Insertion
Description: Patient will have a Nexplanon inserted within 15 minutes of her abortion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post-op Nexplanon Insertion
Description: Place Nexplanon at post operative visit rather than at surgery
Study: NCT00005592

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 90-Y-ibritumomab tiuxetan
Description: IDEC-Y2B8 is a mouse monoclonal antibody with small particles of radioactivity that join to the CD20 antigens on lymphoma cells. It is used to deliver radiation therapy to kill lymphoma cells. This is a one time intravenous infusion for eligible patients and is given over a ten-minute time period.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Rituxan is a mouse/human monoclonal antibody and reacts with the CD20 antigens found on lymphoma cells and causes the body's immune system to destroy the lymphoma cells. It is infused at a dose of 250 mg/m2 followed by a second infusion approximately one week later of the same dose.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: indium In 111 ibritumomab tiuxetan
Description: IDEC-In2B8 is a mouse monoclonal antibody that contains Indium, routinely used in nuclear medicine. It is given as a one-time intravenous injection over a ten-minute time period immediately following a Rituxan infusion. The physician will then be able to see and evaluate the location and concentration of the antibody in the body.
Study: NCT03323307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT imaging
Description: imaging of retina using OCT device
Study: NCT02887846

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heated Humidified High-Flow Nasal Cannula
Description: Patients requiring mechanical ventilation for at least 6 hours on the first 7 postnatal days will be included in the study.When patients were Fi O2 \< 0,40, Pa CO2 \< 65 mmHg, pH\> 7.20, MAP (mean airway pressure) \<7 cm H2O, they will be extubated if statistically stable.Oxygen-air mixture of 4-6 l / min flow rate will be set in HHHFNC group, and pressure will be set to 5-8 cm H2O in NCPAP group. When flow is 2 l / min, FiO2 is\<0.30 at 24 hours and above, free oxygen will be introduced. In NCPAP group, when pressure is 5 cm H2O and FiO2 \< 0.30 at 24 hours and above, free oxygen will be introduced.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heated Humidified High-Flow Nasal Cannula
Description: Patients requiring mechanical ventilation for at least 6 hours on the first 7 postnatal days will be included in the study.When patients were Fi O2 \< 0,40, Pa CO2 \< 65 mmHg, pH\> 7.20, MAP (mean airway pressure) \<7 cm H2O, they will be extubated if statistically stable.Oxygen-air mixture of 4-6 l / min flow rate will be set in HHHFNC group, and pressure will be set to 5-8 cm H2O in NCPAP group. When flow is 2 l / min, FiO2 is\<0.30 at 24 hours and above, free oxygen will be introduced. In NCPAP group, when pressure is 5 cm H2O and FiO2 \< 0.30 at 24 hours and above, free oxygen will be introduced.
Study: NCT03245788

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lay Navigation
Description: Patients who are assigned to intervention will be contacted by a navigator who will explain and offer their services to the patient. Navigators focus efforts on supporting patients in self-management and in supporting non-medical needs.
Study: NCT03700892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cinnamaldehyde e-liquid
Description: Participants will inhale an e-liquid that contains cinnamaldehyde from Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cinnamaldehyde e-liquid
Description: Participants will inhale an e-liquid that contains cinnamaldehyde from Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PG/VG e-liquid
Description: Participants will inhale an e-liquid that contains PG/VG from the Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PG/VG e-liquid
Description: Participants will inhale an e-liquid that contains PG/VG from the Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).
Study: NCT02955186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saracatinib
Description: Saracatinib 125 mg once per day for 8 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo once per day for 8 days
Study: NCT04646317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine injection
Description: Infusion of dexmedetomidine will be prepared in Four syringes of 50ml containing dexmedetomidine in concentration of 1 microgram per millilitre.
Study: NCT03133468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJM347
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJM347
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJM347
Description: Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration
Study: NCT04646317

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% as placebo
Study: NCT03045484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone
Description: CRO is effective for 12 h. Patient takes it only twice a day. The minimum oral unit of CRO is a 10 mg tablet, so the minimum daily dose was 10 mg.
Study: NCT00780442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: 50 mg DCS

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00463541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin succinate
Description: oral
Study: NCT04141579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab 140 MG/ML [Repatha]
Description: Evolocumab (also known as Repatha, formerly referred to as AMG 145) is a human monoclonal immunoglobulin G2 (IgG2) that specifically binds to proprotein convertase subtilisin/kexin type 9 (PCSK9) preventing its interaction with the low-density lipoprotein receptor (LDLR). The inhibition of PCSK9 by evolocumab leads to increased LDLR expression and subsequent decreased circulating concentrations of low-density lipoprotein cholesterol (LDL-C).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT02145481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Decision aid describing treatment choices for patients with coronary artery disease.
Study: NCT03045484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone
Description: CRO is effective for 12 h. Patient takes it only twice a day. The minimum oral unit of CRO is a 10 mg tablet, so the minimum daily dose was 10 mg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: Radiotherapy were administered intensity modulated radiation therapy wiht a dose of 1.8-2.2Gy per fraction, 30-32 fraction for various tumor locations. Chemotherapy drugs platinum was used once a weak with 100mg/㎡.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: Radiotherapy were administered intensity modulated radiation therapy wiht a dose of 1.8-2.2Gy per fraction, 30-32 fraction for various tumor locations. Chemotherapy drugs platinum was used once a weak with 100mg/㎡.
Study: NCT02145481

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CAD Education
Description: Education for patients with coronary artery disease
Study: NCT00925028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Patients of group A will have the task of managing their own warfarin therapy using the provided nomograms. In the second office visit patients will be told to which group they were randomized and if they are in group A they will then be instructed on how to use the warfarin adjustment nomograms provided. After four months the groups will switch to the alternate management strategy. Patients in both groups will use warfarin tablets of two dosage strengths, 1 mg and 5 mg. All INR testing will be done at the community laboratory and results will be made available to the patient for dosage adjustment, as well as the physician. The physician's office will be available for appointments and phone calls from study subjects to discuss and support the process at any time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Patients of group B will continue to be managed by their physician. This time those in group B will be instructed on how to use the nomograms during an office visit. Patients in both groups will use warfarin tablets of two dosage strengths, 1 mg and 5 mg. All INR testing will be done at the community laboratory and results will be made available to the patient for dosage adjustment, as well as the physician. The physician's office will be available for appointments and phone calls from study subjects to discuss and support the process at any time.
Study: NCT01723553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-11 PiB
Description: One time intravenous administration of \~740 megabecquerel (MBq) of \[N-methyl-C-11\]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (PiB) (range 370 - 740 MBq).
Study: NCT00680056

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol plus Placebo (Tiotropium)
Description: Formoterol 12mcg-capsules (2x/d) + Placebo (Tiotropium) (1x/d). Double-blind medication will be dispensed in HandiHalers and Aerolisers during 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol plus Tiotropium
Description: Formoterol 12mcg-capsule (2x/dia) + Tiotropium 18mcg-capsule (1x/d). Double-blind medication will be dispensed in HandiHalers and Aerolisers during 2 weeks.
Study: NCT02552849

Intervention type: OTHER
Intervention: No intervention
Study: NCT03265379

Intervention type: OTHER
Intervention: FACT-B and Brief Pain Inventory
Description: Quality of Life Questionnaires

Intervention type: OTHER
Intervention: FACT-B and Brief Pain Inventory
Description: Quality of Life Questionnaires

Intervention type: OTHER
Intervention: FACT-B and Brief Pain Inventory
Description: Quality of Life Questionnaires

Intervention type: OTHER
Intervention: FACT-B and Brief Pain Inventory
Description: Quality of Life Questionnaires
Study: NCT00876122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Escalating oral dose
Study: NCT01610973

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endothelial descemet membrane graft
Description: Standard Endothelial descemet membrane graft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endothelial descemet membrane graft
Description: Standard Endothelial descemet membrane graft
Study: NCT02818608

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Functional Electrical Stimulation (FES)
Description: Functional Electrical Stimulation (FES) + Sham Transcranial direct brain stimulation (tDCS)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combination of Transcranial direct brain stimulation (tDCS) and FES
Description: Real Functional Electrical Stimulation (FES) + Real Transcranial direct brain stimulation (tDCS)
Study: NCT02928237

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation tDCS
Description: A battery driven DC stimulator (neuroConn Gmbh,98693 llmenau, Germany)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial direct current stimulation tDCS
Description: A battery driven DC stimulator (neuroConn Gmbh,98693 llmenau, Germany)
Study: NCT04300218

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: internet-delivered cognitive-behavioral therapy for insomnia (iCBT-I)
Description: The 2-month intervention consists of educational material divided into 8 modules, which provide the rationale for the CBT-I interventions: sleep restriction; stimulus control; cognitive techniques; relaxation techniques. Information is presented in 10-minute videolectures.~The program includes a sleep diary to insert bedtime and waketime, sleep latency, total sleep time, night awakenings.~All material will be delivered through the internet program and expected to be elaborated by the patient but with the opportunity to contact a specialist via the feedback form (guidance on request) in a secured environment if they face difficulties or possible negative effects of the intervention. The content of the program is based on an already established internet-based self-help program against insomnia that was already tested in a previous study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: internet-delivered cognitive-behavioral therapy for insomnia (iCBT-I)
Description: The 2-month intervention consists of educational material divided into 8 modules, which provide the rationale for the CBT-I interventions: sleep restriction; stimulus control; cognitive techniques; relaxation techniques. Information is presented in 10-minute videolectures.~The program includes a sleep diary to insert bedtime and waketime, sleep latency, total sleep time, night awakenings.~All material will be delivered through the internet program and expected to be elaborated by the patient but with the opportunity to contact a specialist via the feedback form (guidance on request) in a secured environment if they face difficulties or possible negative effects of the intervention. The content of the program is based on an already established internet-based self-help program against insomnia that was already tested in a previous study.
Study: NCT03264196

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Reduction and Internal Fixation
Description: Surgical treatment of fracture
Study: NCT01305057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pyridoxine tri-isopalmitate
Description: 2% dosage, oil-in-water emulsion, twice a day, 28 days
Study: NCT01150851

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: caloric restriction
Description: 10 to 15% reduction in total daily calories (300 to 500 kcal reduction) from the usual daily energy consumption for 4 months duration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: caloric restriction
Description: 10 to 15% reduction in total daily calories (300 to 500 kcal reduction) from the usual daily energy consumption for 4 months duration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: supervised physical activity for a maximum of 30-45 minutes, 3 times per week for 4 months duration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: supervised physical activity for a maximum of 30-45 minutes, 3 times per week for 4 months duration
Study: NCT00479674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: 100 mg/m2 IV over 30 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death..

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg IV days 1,15 Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria,intolerable toxicity, or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: area under curve (AUC)=2 IV over 15 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death.
Study: NCT04877145

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: drill
Description: single 3.25 mm stainless steel drill

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: drill
Description: single 3.25 mm stainless steel drill
Study: NCT01071265

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Preconditioning
Description: Occlusion of leg blood flow using a pneumatic tourniquet on the thigh. Tourniquets are inflated to 300 mmHg for 5 minutes followed by deflation for 5 minutes then repeated for a total of 3 inflations.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham
Description: Sham procedure. A pneumatic tourniquet is placed on an upper arm and/or thigh but not inflated.